Correlation Between Microsoft and Cannara Biotech

Can any of the company-specific risk be diversified away by investing in both Microsoft and Cannara Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and Cannara Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Microsoft and Cannara Biotech, you can compare the effects of market volatilities on Microsoft and Cannara Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of Cannara Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and Cannara Biotech.

Diversification Opportunities for Microsoft and Cannara Biotech

-0.27

Correlation Coefficient

Microsoft  Cannara Biotech

Very good diversification

The 3 months correlation between Microsoft and Cannara is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and Cannara Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cannara Biotech and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with Cannara Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cannara Biotech has no effect on the direction of Microsoft i.e., Microsoft and Cannara Biotech go up and down completely randomly.

Pair Corralation between Microsoft and Cannara Biotech

Given the investment horizon of 90 days Microsoft is expected to generate 0.27 times more return on investment than Cannara Biotech. However, Microsoft is 3.69 times less risky than Cannara Biotech. It trades about 0.06 of its potential returns per unit of risk. Cannara Biotech is currently generating about 0.01 per unit of risk. If you would invest  36,854  in Microsoft on September 4, 2024 and sell it today you would earn a total of  6,266  from holding Microsoft or generate 17.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Microsoft  vs.  Cannara Biotech

Microsoft

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Microsoft are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Microsoft is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Cannara Biotech

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Cannara Biotech are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Cannara Biotech reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Microsoft and Cannara Biotech

The main advantage of trading using opposite Microsoft and Cannara Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, Cannara Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cannara Biotech will offset losses from the drop in Cannara Biotech's long position.

The idea behind Microsoft and Cannara Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.